Embecta Corp. (NASDAQ: EMBC) has announced changes to its board of directors, with David J. Albritton resigning due to personal reasons and Lt. Gen. (Ret.) David F. Melcher choosing not to stand for re-election at the 2026 annual stockholder meeting. Both individuals have been directors since the board's inception in 2022.
Devdatt "Dev" Kurdikar, President and CEO, expressed gratitude for their contributions to the company, particularly thanking David Albritton for shaping the corporate identity and communication efforts, and Lt. Gen. Melcher for his leadership and mentoring during the company's stand-up phase.
Upon Lt. Gen. Melcher's departure, the board expects to appoint Mr. Kurdikar as chairman and Dr. Claire Pomeroy, who has also been on the board since its inception, as lead independent director. The corporate governance and nominating committee will assess any potential replacements for the departing directors.
Embecta, a global company with approximately 2,000 employees, is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, focusing on improving lives through innovative solutions and partnerships. As a result of these announcements, the company's shares have moved 1.12% on the market, and are now trading at a price of $14.47. Check out the company's full 8-K submission here.
